Laurus Labs Limited
LAURUSLABS
Kedudukan dalam Saham
#1737
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Harga Saham
$22.83
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$12.34B
Perubahan (1 hari)
0.51%
Perubahan (1 tahun)
117.95%
Negara
IN
Perdagangan Laurus Labs Limited (LAURUSLABS)
Kategori
Healthcare
Nisbah P/E bagi Laurus Labs Limited (LAURUSLABS)
Nisbah P/E pada October 2026 TTM: 100.45
Menurut laporan kewangan dan harga saham terkini Laurus Labs Limited, nisbah P/E semasa (TTM) ialah 100.45. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 136.45.
Sejarah nisbah P/E bagi Laurus Labs Limited dari 2013 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 100.45 | 11.37% |
| 2025 | 90.20 | -33.90% |
| 2024 | 136.45 | 584.38% |
| 2023 | 19.94 | -47.92% |
| 2022 | 38.28 | 94.14% |
| 2021 | 19.72 | 45.26% |
| 2020 | 13.57 | -69.76% |
| 2019 | 44.89 | 39.70% |
| 2018 | 32.13 | 30.85% |
| 2017 | 24.56 | -15.80% |
| 2016 | 29.16 | -32.80% |
| 2015 | 43.40 | 43.54% |
| 2014 | 30.23 | -31.70% |
| 2013 | 44.27 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -65.20% |
IN
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.